Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

I think the American and Canadian trials would be huge. A game changer really. I think the team needs to discuss the South Korean trial enrollment during the BioPub interview. South Korea doesn't currently have enough new cases per day to actually provide enough patients that are as sick as required by the trial. I know they only want 40. But they want 40 sick patients. There are less than 10 regular cases per day, and im sure a fraction are sick. Not to mention, its one investigator at a single hospital. The less than 10 per day is for the country. Anyway, that's my only consideration at this point.

Canada and US both still have enough sick patients, so I think the emphasis needs to be placed there.

I would expect volatility in the short term as a result. Especially if the South korea trial gets halted early for not being able to enroll patients. But if you're holding long then it won't matter because hopefully your have canada and usa and then IPF stuff.